Literature DB >> 32424495

Latent Autoimmune Diabetes in Adults: A Review of Clinically Relevant Issues.

Marta Hernández1,2,3, Dídac Mauricio4,5.   

Abstract

Latent autoimmune diabetes in adults (LADA) is still a poorly characterized entity. However, its prevalence may be higher than that of classical type 1 diabetes. Patients with LADA are often misclassified as type 2 diabetes. The underlying autoimmune process against β-cell has important consequences for the prognosis, comorbidities, treatment choices and even patient-reported outcomes with this diabetes subtype. However, there is still an important gap of knowledge in many areas of clinical relevance. We are herein focusing on the state of knowledge of relevant clinical issues than may help in the diagnosis and management of subjects with LADA.

Entities:  

Keywords:  Adults; Clinical management; Diabetes complications; Diabetes mellitus; Diagnosis; Glutamic decarboxylase autoantibodies (GADA); LADA; Latent autoimmune diabetes in adults; Patient-reported outcomes; Quality of life; Treatment

Mesh:

Year:  2021        PMID: 32424495     DOI: 10.1007/5584_2020_533

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

1.  Diabetes duration and the risk of dementia: a cohort study based on German health claims data.

Authors:  Constantin Reinke; Nikolaus Buchmann; Anne Fink; Christina Tegeler; Ilja Demuth; Gabriele Doblhammer
Journal:  Age Ageing       Date:  2022-01-06       Impact factor: 10.668

2.  Genetics: Is LADA just late onset type 1 diabetes?

Authors:  M Hernández; Y Nóvoa-Medina; R Faner; E Palou; A Esquerda; E Castelblanco; A M Wägner; D Mauricio
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-10       Impact factor: 6.055

3.  Latent Autoimmune Diabetes in Adults: Background, Safety and Feasibility of an Ongoing Pilot Study With Intra-Lymphatic Injections of GAD-Alum and Oral Vitamin D.

Authors:  Anneli Björklund; Ingrid K Hals; Valdemar Grill; Johnny Ludvigsson
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-18       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.